A carregar...
Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care
Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4041675/ https://ncbi.nlm.nih.gov/pubmed/24821824 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0059 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|